READ-ONLY DIGITIZATION RESULT
The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.
BMC Cancer · 2025-Aug-25 · PMID 40851062
Panel F提取完成待 EXE 对齐验证
Overall survival
Fig. 4 Progression-free survival and overall survival subgroup analysis according to PD-L1 CPS. Progression-free survival in all randomized patients ( A ) and in patients receiving immunotherapy plus chemotherapy ( C ) and placebo plus chemotherapy ( E ). Overall survival in all randomized patients ( B ) and in patients receiving immunotherapy plus chemotherapy ( D ) and placebo plus chemotherapy ( F ). CI, confidence interval; CPS, combined positive score; HR, hazard ratio
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-18T19:58:08+00:00 |